Developed by Sanovas, bronchial thermoplasty is an outpatient procedure that delivers precisely controlled thermal energy to reduce excess airway smooth muscle associated with airway constriction in patients with asthma. By decreasing the ability of the airways to constrict, this new treatment has been shown to help patients with severe asthma gain substantially better control over their disease, according to the company.
Mayo Clinic will participate in technology development, which will be combined with and incorporated into Sanovas’ portfolio of patents and therapy enabling technologies for pulmonary disease. The tenets of the relationship grant Sanovas exclusive worldwide license of the Mayo patent.
“Working together with Sanovas exemplifies how industry collaborations support today’s new era of evidence-based medicine,” said Craig E. Daniels, MD, associate professor of pulmonary and critical care medicine at Mayo Clinic and co-inventor of Mayo’s patent.
“The development of a single treatment system that can be performed with precision and that can offer real time feedback of treatment efficacy in a single office visit, versus the three treatments that are currently required benefits patients and providers because it will reduce risk and save time and money.”